Biotechnology
RVAC Medicines Secures HSA Approval to Initiate Phase 1B Clinical Trial in Singapore
SINGAPORE, Feb. 20, 2023 /PRNewswire/ -- RVAC Medicines Pte. Ltd. (RVAC), a messenger RNA (mRNA) technology platform company, announced today that it has secured the approval from the Health Sciences Authority (HSA) to initiate Phase 1B clinical trial in Singapore to evaluate the safety and immuno...
2023-02-21 10:00
1933
Bridge Biotherapeutics Presents Phase 2a Clinical Trial Results For BBT-401, a Drug Candidate to Treat Ulcerative Colitis
* BBT-401 meets safety endpoints achieved in previous clinical studies * The drug candidate did not achieve an improved clinical response compared to the placebo study group * 54.5% of the treatment cohort exhibited a valid treatment response to orally administered BBT-401 SEONGNAM, South Ko...
2023-02-21 07:00
1769
Celltrion and LISCure Biosciences announce strategic collaboration to develop novel microbiome treatment for Parkinson's disease
* Co-research and co-development of novel microbiome therapeutics * Discovery of new candidates to meet high unmet medical needs in Parkinson's disease SEOUL, South Korea, Feb. 20, 2023 /PRNewswire/ -- LISCure Biosciences Inc., a clinical-stage biotech developing advanced microbiome technology...
2023-02-20 22:00
2050
GC Biopharma Receives WHO Pre-Qualification for BARYCELA
YONGIN, South Korea, Feb. 19, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a leading provider of biopharmaceutical products inSouth Korea, announced today that the World Health Organization (WHO) has granted prequalification for BARYCELA, GC Biopharma's varicella vaccine. WHO prequalificatio...
2023-02-20 09:38
1975
Terumo Blood and Cell Technologies' IMUGARD Platelet Pooling Set Cleared by FDA
IMUGARD to Help Strained U.S. Platelet Supply Meet Growing Need LAKEWOOD, Colo., Feb. 16, 2023 /PRNewswire/ -- Today, Terumo Blood and Cell Technologies announces U.S. Food and Drug Administration (FDA) clearance and official launch of its IMUGARD® WB Platelet Pooling Set, which supports extende...
2023-02-17 03:48
2011
GLOBAL SARCOMA THERAPY NOW APPROVED FOR NEW ZEALAND PATIENTS
* Globally regarded soft-tissue sarcoma therapy has been approved by Medsafe forNew Zealand patients * YONDELIS® (trabectedin) demonstrates 45% reduction in risk of disease progression or death versus dacarbazine[1] SINGAPORE and AUCKLAND, New Zealand, Feb. 16, 2023 /PRNewswire/ -- Independen...
2023-02-17 03:00
2329
WuXi AppTec Named "Industry Mover" in S&P Global Sustainability Yearbook 2023
SHANGHAI, Feb. 15, 2023 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services for the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, announced today that it ...
2023-02-16 08:00
2000
Inventia Life Science collaborates with MSD to develop 3D advanced cell models for neurodegenerative disease drug discovery
Collaboration to develop 3D in vitro models of the brain for the discovery of
therapeutic candidates using Inventia's novel 3D cell culture platform, RASTRUM™
SYDNEY, Feb. 15, 2023 /PRNewswire/ -- February 16, 2023, Inventia Life Science
2023-02-16 06:00
2489
AnPac Bio-Medical Science Acquires GISN (HK) LIMITED, a Technical Solution and Outsourcing Consulting Services Provider
NEW YORK, Feb. 15, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations inthe United States andChina focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platfo...
2023-02-15 21:00
3416
Eluminex Biosciences Announces Completion of Initial Enrollment in Part A of the CLARITY Study Evaluating a Human Recombinant Collagen-derived (rhCIII) Biosynthetic Cornea (EB-301)
Initial Part A results to be presented at the upcoming American Society of Cataract and Refractive Surgery Annual Meeting EB-301 has the potential to be the world's first approved rhCIII biosynthetic corneal implant for the treatment of corneal blindness SUZHOU, China and SAN FRANCISCO, Feb. 14,...
2023-02-15 01:00
1889
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma
Approval follows U.S. FDA clearance of IND application for BCMA/CD19 dual-targeting FasTCAR-T GC012F Company plans to initiate Phase 1/2 clinical trial in China in third quarter of 2023 SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Feb. 13, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ...
2023-02-13 20:30
2134
Vmade Launched Cooperation with Fulgent Life to Build a Cross-Border SaaS and Payment Integration Solution for Private Growth
BEIJING, Feb. 13, 2023 /PRNewswire/ -- WeTrade Group Inc. ("WeTrade" or the
"Company") (NASDAQ: WETG
2023-02-13 20:00
2346
HanAll Biopharma Invests in Interon to Seek Collaboration Opportunities
* HanAll will invest in Interon Laboratories, a preclinical-stage biotechnology company focused on treating complex neurological disorders * Interon is developing a new category of immunotherapy for people with neurological and immune disorders starting with autism spectrum disorder SEOUL, So...
2023-02-10 20:00
2998
Nona Biosciences Enters into HCAb Based Antibody Discovery Collaboration Agreement with Mythic Therapeutics
CAMBRIDGE, Mass., Feb. 10, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to cutting edge technology innovations, and providing a total solution from "Idea to IND" ("I to ITM"), today announced that it has entered into a collaboration agreement ...
2023-02-10 13:00
2173
Technoderma Medicines Initiates TDM-180935 Atopic Dermatitis Clinical Program with Phase 1 Dose Escalation Trial
SAN DIEGO, Feb. 9, 2023 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report the Company has begun dosing healthy volunteer subjects in its Phase 1 clinical trial of topical TDM-180935 ointment. This first clinical trial in ...
2023-02-09 21:00
1687
AnPac Bio-Medical Science Enters into Definitive Agreement to Acquire Fresh2 Ecommerce Inc, a B2B Asian Food E-commerce Platform
Transaction expected to fuel the Company's growth in the U.S. food market NEW YORK, Feb. 9, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations inthe United States andChina focused on early cancer screening and detection and plans to ...
2023-02-09 21:00
3135
GC Biopharma Receives WHO Pre-Qualification for Filling and Finish Plant in Ochang, South Korea
YONGIN, South Korea, Feb. 8, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a leading provider of biopharmaceutical products inSouth Korea, announced today that the World Health Organization (WHO) has awarded prequalification to filling and finish plant onFebruary 3 2023, located in Ochang, South...
2023-02-09 09:21
1960
ReviR Therapeutics and Asieris Pharmaceuticals Enter into Agreement to Discover Oncology Therapeutics Based on ReviR's Comprehensive Approach to RNA-targeted Technologies
SAN FRANCISCO, Feb. 8, 2023 /PRNewswire/ -- ReviR Therapeutics, a privately held developer of a suite of small molecule RNA-targeting technologies for cancer and other genetically-defined diseases, and Asieris Pharmaceuticals, a global biopharma company specializing in discovering, developing, an...
2023-02-08 22:00
2110
SK bioscience Announces the Largest Investment Ever to Establish Songdo Global Research & Process Development Center
* The additional investment for the 'R&PD Center' was confirmed by the board of directors committee with a total of261 million USD * SK bioscience plans to establish a vaccine-biopharmaceutical hub, organizing a global cooperative model against new pandemics SEONGNAM, South Korea, Feb. 8, 202...
2023-02-08 20:00
2015
Infectious disease specialist Dr. Regis A. Vilchez is appointed CMO of MicuRx Pharmaceuticals, Inc.
SHANGHAI, Feb. 8, 2023 /PRNewswire/ -- Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx," 688373) announced recently that it has appointedRegis A. Vilchez, MD, PhD, an experienced R&D biopharmaceutical executive and infectious disease expert, as Chief Medical Officer of its American subsidiary, ...
2023-02-08 16:05
2423
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7120
